Skip to main content
Premium Trial:

Request an Annual Quote

Elucidata to Support Auron Therapeutics in Cancer Data Analysis

NEW YORK (GenomeWeb) – Elucidata, a developer of analytics software to support drug discovery, has signed a four-year contract with startup biotech firm Auron Therapeutics to provide data analytics for differentiation-based cancer therapies. Financial terms were not disclosed.

Wellesley, Massachusetts-based Auron Therapeutics, which launched this year, will leverage Elucidata's cloud-based data analytics platform called Polly to to analyze transcriptomic, metabolomic, and epigenetic data from biological samples, the companies said. Auron is seeking to identify and validate targets for differentiation-based therapy for acute myeloid leukemia and eight other types of cancer.

"With our platform, we are seeking to develop an atlas of differentiation paths of healthy and diseased cells that will help us identify and characterize disease mechanisms," Elucidata Cofounder and CEO Abhishek Jha said in a statement. "This collaboration with Auron is an incredible opportunity to realize the promise of big-data analytics to discover new targets that will deliver more precise medicine to patients."

Cambridge, Massachusetts-based Elucidata raised $1.7 million in a seed funding round that closed in June.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.